From substance to process: A meta-ethnographic review of how healthcare professionals and patients understand placebos and their effects in primary care. by Hardman, D.I. et al.
  
 
 
 
 
 
 
From substance to process: a meta-ethnographic review of how healthcare professionals and 
patients understand placebos and their effects in primary care 
  
  
 Abstract  
Research suggests that a ‘placebo’ can improve conditions common in primary care including 
pain, depression, and irritable bowel syndrome. However, disagreement persists over the 
definition and clinical relevance of placebo treatments. We conducted a meta-ethnographic, 
mixed-research systematic review to explore how healthcare professionals and patients 
understand placebos and their effects in primary care. We conducted systematic literature 
searches of five databases – augmented by reference chaining, key author searches, and 
expert opinion – related to views on placebos, placebo effects, and placebo use in primary 
care. From a total of 34 eligible quantitative, qualitative and mixed-methods articles reporting 
findings from 28 studies, 21 were related to healthcare professionals’ views, 11 were related 
to patients’ views, and two were related to both groups. In the studies under review, 
healthcare professionals reported using placebos at markedly different frequencies. This was 
highly influenced by how placebos were defined in the studies. Both healthcare professionals 
and patients predominantly defined placebos as material substances such as ‘inert’ pills, 
despite this definition being inconsistent with current scientific thinking. However, healthcare 
professionals also, but less prevalently, defined placebos in a different way: as contextual 
processes. This better concurs with modern placebo definitions, which focus on context, 
ritual, meaning, and enactivism. However, given the enduring ubiquity of substance 
definitions, for both healthcare professionals and patients, we question the practical, clinical 
validity of stretching the term ‘placebo’ towards its modern iteration. To produce ‘placebo 
effects’, therefore, primary healthcare professionals may be better off abandoning placebo 
terminology altogether. 
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Introduction 
The placebo concept has a long history (Shapiro and Shapiro, 1997), but our modern notion is 
grounded in how we validate the existence of therapeutic effects through the use of the 
Randomised Controlled Trial (RCT) (Miller and Brody, 2011). In a RCT a particular 
mechanism – often a drug mechanism – is isolated by controlling for other factors that might 
influence the outcome of the trial, including, for example, natural history and regression to 
the mean. By using a ‘placebo’ to control for these factors, the RCT has been an effective 
tool in the advancement of modern medicine (Friedman et al., 2015; Pocock, 1983). 
However, in order to isolate the particular mechanism under investigation, this process of 
establishing treatment and control groups in a certain way also controls for contextual or 
social effects that can occur naturally during treatment; for example, the effects of empathic 
care, a patient’s belief in a treatment, and the method of administration (Walach et al., 2006; 
Avins et al., 2012; Howick, 2009). It is the natural occurrence of something like these 
‘placebo’ effects, and the idea that they can be deliberately induced in clinical practice, that is 
the focus of this review. 
 Research suggests that a ‘placebo’ can lead to improvements in conditions often 
treated in primary care environments, including pain (Benedetti, 1996), depression (Kirsch et 
al., 2002) and irritable bowel syndrome (Kaptchuk et al., 2010). However, disagreement 
persists over the definition of placebos and their effects (Kirsch, 1997; Moerman and Jonas, 
2002; Grünbaum, 1986; Kaptchuk and Miller, 2015; Shapiro and Shapiro, 1997; Colloca and 
Miller, 2011b), and the efficacy and ethics of using placebos in clinical practice (Colloca and 
Miller, 2011a; Miller and Colloca, 2009). A previous review suggests that the frequency and 
circumstances of placebo use in clinical practice vary substantially, that attitudes among 
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healthcare professionals and patients differ considerably, and that there is no clear definition 
of placebos in clinical practice (Fässler et al., 2010). In this environment whereby the 
definition, efficacy and ethics of clinical placebo treatment remain contentious, both the 
American Medical Association (Bostick et al., 2008) and the British Medical Association 
(Brannan et al., 2012) currently prohibit the practice of ‘placebo prescribing’ or ‘placebo use’ 
without patient consent. 
 Given the tantalising yet unproven potential for improving patient outcomes by using 
placebos in clinical practice, particularly in primary care, we conducted a systematic review 
of how healthcare professionals and patients understand placebos and their effects in primary 
care. Our aims are to: 
1. Conceptualise how healthcare professionals and patients understand placebos, placebo 
use, and placebo effects in primary care; 
2. Explore the consequences of how healthcare professionals and patients understand 
placebos, placebo use, and placebo effects in primary care; and 
3. Generate new insights into how we conceive of placebos and their effects in primary 
care.   
Methods 
Given the conceptual ambiguity in the literature, we conducted an abductive (i.e. 
orientated towards theory generation), mixed-research synthesis, in which diverse findings 
from both qualitative and quantitative studies are arranged into a coherent theoretical 
interpretation (Sandelowski et al., 2012; Pluye and Hong, 2014). This was operationalised 
using a meta-ethnographic methodology (Noblit and Hare, 1988) situated within a theoretical 
framework of American pragmatism, whereby a concept is clarified by equating its meaning 
with the practical implications of its conceived effects (Peirce, 1878/1982). 
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Methodology 
 Meta-ethnography is a flexible approach to synthesis, in which both inductive and 
abductive modes of non-necessary inference (whereby the certainty of formal logic is traded 
for the possibility of new knowledge) are possible. Although initially used for synthesising a 
small number of conceptually rich studies, meta-ethnography is now widely used in 
healthcare to synthesise larger literatures (Atkins et al., 2008; France et al., 2014). And 
although initially intended to only synthesise qualitative studies, there is no epistemological 
reason why it cannot be used in a mixed research synthesis, as in this review (Sandelowski et 
al., 2012; Dixon-Woods et al., 2004). 
In meta-ethnography, studies are not just combed for themes that might be similar or 
different, analysis is instead focussed on actions and processes in their social and historical 
context (Noblit and Hare, 1988). A meta-ethnographic approach can be directly linked with 
grounded theory methodology. Indeed, Noblit and Hare (1988: p.63) make this link in the 
initial monograph, noting that “this is the same as basic theorizing in qualitative research and 
is conceptualized… as… grounded theory.”.  Because grounded theory “comprises a 
systematic… and comparative approach for conducting inquiry for the purposes of 
constructing theory” (Bryant and Charmaz, 2007: p.1) and focuses on “analysing actions and 
processes rather than themes and structure” (Charmaz, 2014: p.15), conceiving of meta-
ethnography through the prism of grounded theory could make the approach more accessible. 
We have explored the selection of meta-ethnography in more detail in a recent methods case 
study (Hardman and Bishop, 2018). Terminology debates notwithstanding, given the 
complexity and uncertainty surrounding placebos and their effects in primary care, a meta-
ethnographic approach is well suited to this review. 
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Inclusion and exclusion criteria 
Table 1 shows inclusion and exclusion criteria. We focussed on the views of 
healthcare professionals and patients in the context of primary care, in line with our research 
aims. We excluded clinical trials and laboratory based placebo studies because they do not 
directly capture the views of healthcare professionals and patients. We excluded qualitative 
studies nested in clinical trials because such studies focus on views of placebos in trials, not 
clinical practice (e.g., Bishop et al., 2012). We excluded studies based in hospitals and other 
secondary or tertiary care settings to restrict findings to primary care. 
Table 1: Inclusion and exclusion criteria 
 Inclusion criteria Exclusion criteria 
Population Healthcare professionals, patients, or potential patients 
 
Phenomena of interest Views on placebo effects, placebo response, placebo use 
 
Context Primary care 
Placebo controls in clinical trials 
Laboratory based placebo studies  
Study design Empirical studies 
Non-published studies 
RCTs 
 
Search strategy 
 Systematic literature searches, with no date limits, were conducted in January 2017. 
The overall strategy reflects guidance on literature searching for meta-ethnographies (Atkins 
et al., 2008; Malpass et al., 2009; Campbell et al., 2011) and mixed method syntheses (Pope 
et al., 2007; Dixon-Woods et al., 2006a; Dixon-Woods et al., 2006b). We searched five 
electronic databases (CINAHL, MEDLINE, Embase, PsychINFO, and Web of Science – see 
Appendix 1 for specific strategies), conducted reference chaining and key author searches of 
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first authors, and sought expert opinion by emailing members of the Society for 
Interdisciplinary Placebo Studies. 
Screening and selection 
First, studies were screened by title and abstract by the primary author (DH) and a 
second reviewer (AG). Then, suitable studies were screened by full text. Discrepancies were 
resolved by discussion among DH, AG, GL and FB. Examples of discrepancies included 
disagreement on whether studies were in the context of primary care, and whether the 
phenomenon of interest was placebos or other closely related phenomena such as 
complementary and alternative medicine. 
Quality assessment 
 Studies were appraised using the Mixed Methods Appraisal Tool (MMAT) (Pluye et 
al., 2011), designed for appraising and describing the methodological quality of quantitative 
and qualitative studies for systematic reviews.  Early testing suggests it is a reliable tool (Pace 
et al., 2012). DH appraised all studies, and FB, AG, and GL each appraised a proportion of 
studies; we reached agreement through discussion. Examples of topics discussed in this 
process included the categorisation of studies (see Appendix 3 for a list of these categories), 
and the application of various quality criteria, including consideration given by researchers to 
context and the appropriate use of measures. Any intractable issues were resolved by majority 
consensus. However, in line with other meta-ethnographies (Atkins et al., 2008; Malpass et 
al., 2009) we did not exclude studies based on the appraisal, but instead integrated potential 
limitations into the synthesis. 
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Data extraction 
DH formally extracted the following data from all included papers: author, year of 
publication, country, setting, aims, participants, data collection methods, and main findings. 
This was checked by FB. We read the studies chronologically as the concept of ‘placebo 
effects’ has developed significantly over time (Benedetti, 2014; Shapiro and Shapiro, 1997). 
Analysis and synthesis 
Analysis and synthesis were orientated in three phases (Noblit and Hare, 1988): 
determining how the studies are related; translating the studies into each other; and 
synthesising the translations. On commencing the analysis there was potential for one of the 
following syntheses, depending on the initial findings (Noblit and Hare, 1988): reciprocal, 
when findings from studies are similar and can be directly translated into one another; 
refutational, when findings from studies are dissimilar or contradictory, and lines-of-
argument, when findings from studies have similarities and differences and a new context is 
produced. 
We operationalised this iterative process by adapting Charmaz’s (2014) 
constructionist grounded theory analysis approach (see Figure 1). Coding was conducted not 
with the aim of being exhaustive, but as a mode by which dominant findings could emerge. 
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Figure 1: Data analysis and synthesis 
 
Initial coding was conducted by DH. We used the method of constant comparison 
(Glaser and Strauss, 1967/2009) to create focussed codes, which included the most frequent 
or significant initial codes. These informed the creation of categories, which are significant 
focussed codes or patterns interpreted from several codes. We discussed these categories in 
data meetings, and from these discussions and subsequent analysis we created theoretical 
concepts (analytic ideas that offer an explanation for the data) which informed the synthesis. 
To overcome the incommensurable quantitative and qualitative primary data in a 
mixed research synthesis, and in line with a meta-ethnographic approach, we focussed 
analysis at Schutz’s (1973) level of second-order constructs, which are the original study 
authors’ interpretations of their data. Interpretations emerging from the review were deemed 
third order constructs, or “interpretations of interpretations of interpretations” (Noblit and 
Hare, 1988: p.35). Unlike in some meta-ethnographies, we considered direct participant 
quotes presented in the studies to be second order constructs; by the time these data are 
presented in a paper they have already been selected by researchers and removed from their 
original context, which necessarily involves interpretation.  
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Results 
Searches 
Search results are in an adapted PRISMA flow-chart (Moher et al., 2009), in Figure 2. 
 
 
Figure 2: PRISMA flowchart 
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Study characteristics 
 The characteristics of included studies are shown in Table 2 (see Appendix 2 for an 
expanded table including a summary of study main findings). From 34 eligible articles 
reporting findings from 28 studies, 21 were related to healthcare professionals’ views, 11 
were related to patients’ views, and two were related to both healthcare professionals’ and 
patients’ views. Twenty seven were broadly quantitative, six qualitative, and one mixed 
methods. Methods of data collection included surveys (n = 30), interviews (n = 4), focus 
groups (n = 1), and ethnographic observation (n = 1). 
Quality assessment 
 The results of the quality assessment were variable (see Appendix 3). Some studies 
were well designed and conducted, but we assessed some as being of low quality. Most of the 
survey-based studies we assessed to be of low quality had a combination of unrepresentative 
samples and low response rates. And some qualitative studies we assessed to be of low 
quality generally lacked contextual and reflective considerations. However, some studies that 
were intuitively interesting, and which contributed rich data to the review, scored badly on 
the assessment. For example, one ethnographic study (Comaroff, 1976) did not meet the 
initial screening criteria yet was influential. This highlighted one limitation of the MMAT: 
the strict requirement for clear research questions and objectives necessarily precludes more 
exploratory modes of inquiry, such as ethnography. This emphasises the limitations of 
conducting a quality assessment in a meta-ethnography and supports recent practice not to 
exclude studies based on formal quality assessment results (Atkins et al., 2008; Malpass et 
al., 2009).
12 
 
Table 2: Characteristics of eligible articles (n=34) 
 Source article Country Setting Participants (n) Methods of data collection Aims 
1 (Shapiro and Struening, 1973a) USA 
General practice 
Hospitals 
Research 
Psychiatrists (119) 
Internists (50)     
GPs (14)       
Surgeons (16) 
Quantitative survey To investigate differences in the definition and conception of placebos among physicians. 
2 (Shapiro and Struening, 1973b) USA 
General practice 
Hospitals 
Research 
Psychiatrists (117)  
Internists (50)        
GPs (14)       
Surgeons (14) 
Quantitative survey To assess ethical attitudes towards the use of placebos in treatment and research. 
3 (Shapiro and Struening, 1974) USA 
General practice 
Hospitals 
Research 
Psychiatrists (114)  
Internists (48)        
GPs (15)       
Surgeons (14) 
Quantitative survey To assess the tendency of physicians to attribute the use of placebos or nonspecific treatment to other physicians. 
4 (Comaroff, 1976) UK General practice GPs (51) 
Qualitative 
observation 
Interviews 
To investigate how doctors, as placebo prescribers, perceive 
and employ the placebo concept. 
5 (Thomson and Buchanan, 1982) New Zealand General practice GPs (44) Quantitative survey 
To determine GPs’ basic understanding of the placebo effect 
and their views on the use of placebo treatments. 
6 (Lynoe et al., 1993) Sweden 
Primary healthcare 
centre 
University 
Physicians associated 
with a university (47) 
GPs (47)   
Patients (83) 
Mainly quantitative 
survey with some 
open ended 
questions 
To investigate the attitudes of patients and physicians toward 
placebo treatment. 
13 
 
 Source article Country Setting Participants (n) Methods of data collection Aims 
7 (Hróbjartsson and Norup, 2003) Denmark 
General practice 
Private practice 
Hospitals 
GPs (182) 
Hospital physicians 
(185) 
Private specialists 
(136) 
Quantitative survey To investigate the proportion and types of placebo intervention, conditions of use, and attitudes towards use. 
8 (Nitzan and Lichtenberg, 2004) Israel 
Hospitals 
Community clinics 
Hospital physicians 
(31) 
Head nurses (31) 
Family physicians (27) 
Quantitative survey To gauge the frequency and circumstances of, and attitude towards, placebo use in clinical practice. 
9 (Chen and Johnson, 2009) New Zealand 
Primary Care 
Clinics Patients (211) Quantitative survey 
To examine patients beliefs about the placebo effect, views on 
the use of placebos in clinical practice, and their willingness to 
participate in a placebo-controlled RCT. 
10 (Fässler et al., 2009) Switzerland 
General practice 
Private practice 
Paediatricians (67) 
Urban GPs (41) 
Suburban GPs (55) 
Rural GPs (70) 
Quantitative survey To investigate to what extent and in which way Swiss primary care providers use placebo interventions. 
11 (Ferentzi et al., 2010) Hungary General practice GPs (94) Quantitative survey To investigate how GPs in Hungary perceived some important aspects of their own placebo use. 
12 (Kermen et al., 2010) USA Family practice Family physicians (412) 
Mainly quantitative 
survey with some 
open ended 
questions 
To gain a better understanding of the role of placebos in clinical 
practice on a national level. 
13 (Fässler et al., 2011) Switzerland Primary care  
GPs (232) 
Patients (414) 
Quantitative survey 
with one open-
ended question 
To compare the proportions of patients and physicians who 
would accept therapies that work by enhancing self-healing 
capacities and by exploiting contextual factors. 
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 Source article Country Setting Participants (n) Methods of data collection Aims 
14 (Fent et al., 2011) Switzerland Primary care 
GPs (8) 
Internists (2) 
Paediatrician (1) 
Psychiatrist (1) 
Semi-structured 
interviews 
To explore physicians’ views on the use of placebos in daily 
practice. 
15 (Ferentzi et al., 2011) Hungary General practice GPs (169) Quantitative survey To provide a detailed description of physicians’ attitudes toward, and knowledge of, clinical placebo use. 
16 (Kisaalita et al., 2011) USA University Members of the public (103) 
Quantitative survey 
with experimental 
component 
To examine the acceptability and ethics of placebo treatment for 
pain. 
17 (Babel, 2012) Poland Primary care Primary care physicians (190) 
Quantitative survey 
with experimental 
component 
To identify factors that contribute to the high variability of the 
rates of use of placebo interventions reported in questionnaire 
surveys. 
18 (Kisaalita and Robinson, 2012) USA University 
Members of the public 
(100) 
Quantitative survey 
with open-ended 
question 
To examine the acceptability, efficacy and knowledge of 
analgesic placebo treatments. 
19 (Koteles and Ferentzi, 2012) Hungary Online news site 
Members of the public 
(6104) Quantitative survey 
To assess the attitudes of laypeople toward deceptive clinical 
placebo use. 
20 (Meissner et al., 2012) Germany General practice GPs (208) Quantitative survey To collect data on the use of placebo interventions by GPs in Germany. 
21 (Babel, 2013) Poland Primary care Primary care physicians (169) Quantitative survey 
To investigate the behaviour beliefs and attitudes of Polish 
primary care physicians concerning the use of placebo 
interventions. 
22 (Howick et al., 2013) UK Primary care GPs (783) Quantitative survey To investigate the prevalence of placebo use in UK primary care. 
23 (Hull et al., 2013) USA Primary Care Patients with chronic illness (853) Quantitative survey 
To examine the attitudes of US patients about the use of 
placebo treatments in medical care. 
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 Source article Country Setting Participants (n) Methods of data collection Aims 
24 (Linde et al., 2013) Germany General practice 
GPs (84) 
Internists (3) 
Orthopaedists (1) 
Quantitative survey 
(n=80) 
Cognitive interviews 
(N=7) 
To develop a questionnaire. 
25 (Nitzan et al., 2013) Israel Academic centres Students (344) Quantitative survey 
To investigate the opinions of healthy students regarding the 
acceptability of placebo treatment if they were to experience 
depression. 
26 (Bishop et al., 2014a) UK Community General public (58) Focus groups To identify when and why placebo-prescribing in primary care might be acceptable and unacceptable to patients 
27 (Bishop et al., 2014b) UK General practice GPs (783) Qualitative survey To explore GPs’ perspectives on clinical uses of placebos. 
28 (Linde et al., 2014) Germany Private practice 
GPs (319) 
Internists (311) 
Orthopaedists (305) 
Quantitative survey 
To investigate the use of placebos and non-specific treatments 
among physicians working in private practices in Germany, and 
how such use is associated with the belief in and the use of 
complementary and alternative treatments. 
29 (Tandjung et al., 2014) Switzerland Community Patients (12) 
Semi-structured 
interviews 
To explore patients’ conceptualisation, experiences and attitudes 
regarding the use of placebos in daily clinical practice. 
30 (Linde et al., 2015) Germany Private practice 
Family physicians 
(319) 
Internists (311) 
Orthopaedists (305) 
Quantitative survey 
To investigate to what extent family physicians, internists and 
orthopaedists working in private practice in Germany believe in 
the efficacy of, and use, CAM therapies.  
31 (De Gobbi et al., 2016) Italy General practice GPs (62) Quantitative survey 
To investigate placebo use by general practitioners throughout 
their everyday practice: in particular the frequency of use, 
placebo features, instructions, and conditions of use. 
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 Source article Country Setting Participants (n) Methods of data collection Aims 
32 (Feffer et al., 2016) Israel Outpatient clinic 
Patients with 
depression (96) 
Healthy members of 
the public (114) 
Quantitative survey To assess the acceptability of placebo usage among depressed patients 
33 (Ortiz et al., 2016) USA Primary care Patients (853) Qualitative survey To examine qualitative responses regarding the use of placebo treatments in medical care in a sample of US patients. 
34 (Faria et al., 2017) USA Community Parents (1000) Quantitative survey To assess parental attitudes regarding placebo use in paediatric randomised controlled trials and clinical care. 
 
NB: The following groups of articles each derived from one study: [1 - 3] [11, 15] [22, 27] [23, 33] [28, 30]. 
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Review findings 
Early in the analytic process we divided the analysis into two sub-groups: healthcare 
professionals’ views and patients’ views. In the healthcare professionals subgroup we 
identified three categories and 10 sub-categories. In the patients subgroup we identified three 
categories, seven sub-categories and four secondary sub-categories. These categories, their 
descriptions, and the studies that contributed data are shown in Table 3 (healthcare 
professionals’ views) and Table 4 (patients’ views). Initial findings were diverse, 
necessitating a lines-of-argument synthesis (Noblit and Hare, 1988).
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Table 3: Categories (healthcare professionals’ views) 
 
  
Categories Sub-categories Definition 
Contributing articles 
(numbers correspond to those 
allocated in Table 2) 
Metaphysics 
Placebos as substances Healthcare professionals define placebos as material substances 7, 8, 10-12, 14, 21, 24, 27 
Placebos as processes Healthcare professionals define placebos as processes 4, 7, 8, 10-12, 14, 21, 24, 27, 28 
Placebos as substances and processes Healthcare professionals define placebos as both material substances and processes 10, 20, 27, 31 
Rationale 
To induce therapeutic benefit Placebos used with the intention to induce therapeutic benefit for the patient 4, 10-12, 14, 20, 22 
To manage patients Placebos used with the intention to manage patients 4, 7, 10, 12, 14, 20-22 
To cope with uncertainty Placebos used with the intention to cope with situations in which the healthcare professional has no obvious treatment available 4, 12, 20, 28 
To avoid error Placebos used as a safety net 4, 7 
Context 
Setting The situation in which placebos are used, or placebo use is considered 4, 12, 14, 15, 21, 31 
Patient The type of patient considered in relation to placebos and their effects 7, 12, 14, 15, 21, 31 
Condition The specific medical condition considered in relation to placebos and their effects 12, 14, 31 
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Table 4: Categories (patients’ views) 
 
Categories Sub-categories Secondary sub-categories Definition 
Contributing articles 
(numbers correspond to those 
allocated in Table 2) 
Metaphysics 
Placebos as inert  Defining placebos negatively – as not containing an active agent 13, 18, 23, 29 
Bifurcating nature The tendency to divide nature into two systems and assign them different degrees of reality 9, 19, 23, 26, 29 
Rationale 
Acceptable 
To induce therapeutic benefit 
Believing that for a placebo to be acceptable, the 
healthcare professional must use it with the intention of 
inducing therapeutic benefit for the patient 
6, 9, 25, 26, 33 
To give hope Believing that it is acceptable to use a placebo to give a 
patient hope that they will get better 6, 26 
Unacceptable 
To manage patients Believing that it is unacceptable to use a placebo to manage patients 9, 23 
To save money Believing that it is unacceptable to use a placebo to save 
money 26 
Efficacy 
Patient characteristics  Believing that placebo efficacy is related to patient characteristics 9, 26, 29 
Doubt Doubting that placebos can be effective in treating patients 26, 29, 33 
Wanting to disprove the power of 
placebos 
Linking placebos with a negative image of self and 
wanting to show one cannot be fooled by a ‘placebo’ 26, 29 
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Heterogeneous findings 
In the studies under review, it was especially notable that healthcare professionals 
reported using placebos at markedly different frequencies. For example, in one study 86% of 
healthcare professionals reported using placebos in the last year (Hróbjartsson and Norup, 
2003); in another 56% reported using them at least once (Kermen et al., 2010); and in another 
only 17% reported using them at least once (Fässler et al., 2009). This heterogeneity was 
partly dependent on how placebos were defined in each study; for example, one study 
recorded differences in use of between 97% and 12% (Howick et al., 2013) depending on the 
definition. This suggests that understanding how placebos are defined in primary care is 
essential to understand how they are used and what effects they might have. Before 
investigating the prevalence or effects of placebos, therefore, it is critical to better understand 
how placebos themselves are defined. This is the focus of our review findings. 
Placebo definitions in primary care 
Placebos as substances 
Healthcare professionals and patients predominantly defined placebos as material 
substances (Hróbjartsson and Norup, 2003; Ferentzi et al., 2010; Kermen et al., 2010; Fent et 
al., 2011; Linde et al., 2013; Bishop et al., 2014b; Fässler et al., 2011; Kisaalita and 
Robinson, 2012; Tandjung et al., 2014; Hull et al., 2013; Nitzan and Lichtenberg, 2004; 
Fässler et al., 2009; Babel, 2013). Healthcare professionals indicatively defined a placebo as 
a “pharmacological intervention, for example vitamin tablets, thus reflecting the narrow 
meaning of the term.” (Hróbjartsson and Norup, 2003: p.162), or as “an inert substance that 
when taken by a person can have an effect on that person - either good or bad” (Bishop et al., 
2014b: p.359). Moreover, although in many surveys the definitions were fixed by the 
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researchers, when given an opportunity to define placebos themselves, healthcare 
professionals often focussed explicitly on placebos as inert substances: in one study “the 
majority of PCPs [primary care providers] stated that a placebo is a dummy drug without 
substance.” (Fent et al., 2011: p.3), and another stated that “physicians intuitively equate 
placebo or typical placebo with pure placebo [inert substance]… [and] the cognitive 
interviews clearly confirmed that the concept of impure placebos [substances known to be 
effective for other conditions] is unfamiliar and confusing to physicians.” (Linde et al., 2013: 
p.364). 
Patients also typically defined placebos as inert material substances (Fässler et al., 
2011; Kisaalita and Robinson, 2012; Tandjung et al., 2014; Hull et al., 2013). One indicative 
study stated that, “contrary to how placebo effects are frequently characterized in the 
scientiﬁc community (i.e., psychosocial context and its contribution to treatment efﬁcacy), 
participants in our sample conceptualized placebo effects as predominately inert.” (Kisaalita 
and Robinson, 2012: p.897). Another found that “the definition of placebo given by the 
participants mostly matched the common understanding of a pure placebo.” (Tandjung et al., 
2014: p.1). 
The problems with substance definitions 
The definition of placebos as material substances dominated the studies. The 
dominance of a singular definition is beneficial as it may lead to better mutual understanding 
between healthcare professionals and patients. However, such a substance definition does not 
dominate modern placebo studies research, because many researchers think it untenable and 
ultimately nonsensical. 
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A substance definition is somewhat analogous with the classic definition given by 
Henry Beecher (1955: p.1602), whereby placebos are  “pharmacologically inert substances… 
having a psychological effect”. Our findings suggest that this is still the dominant lay 
definition. However, even if one disregards the untenable mind/body dualism in the 
definition, one quickly runs into problems. First, as other researchers have noted, it is 
conceptually misleading to define any substance as inert, as all substances can be treated in 
physico-chemical terms if one chooses to do so (Howick, 2017; Grünbaum, 1986); for 
example, even the classic sugar pill is not inert to a diabetic. In this sense, the distinction 
between ‘pure’ and ‘impure’ placebos is not just, as our findings suggest, confusing (e.g. 
Linde et al., 2013), but untenable. 
If one accepts, therefore, that nothing is inert, the only credible substance definition 
one is left with is that of ‘impure’ placebos: substances which are known to be effective for 
treating other conditions. However, if we interrogate this version of the substance definition, 
it too breaks down. A classic, and contentious, example of an ‘impure’ placebo is an 
antibiotic given for a viral, rather than a bacterial infection. In the first instance the substance 
(the antibiotic pill) is a placebo, in the latter instance it is not. Yet in both cases it is the same 
substance. In another example, a sugar pill given for a headache is a placebo, but is not when 
put in one’s tea. In both cases it cannot be that the substance itself is the placebo, that is 
paradoxical, as the same substance is placebo and non-placebo in different situations. 
‘Impure’ placebos, therefore, are as untenable as ‘pure’ ones. However, in the studies under 
review, healthcare professionals also conceived of placebos in a less paradoxical way. 
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Placebos as processes 
Although healthcare professionals commonly defined placebos as material substances, 
they also, although much less commonly, defined placebos in a different way: as processes 
(Comaroff, 1976; Hróbjartsson and Norup, 2003; Nitzan and Lichtenberg, 2004; Fässler et 
al., 2009; Ferentzi et al., 2010; Kermen et al., 2010; Fent et al., 2011; Babel, 2013; Linde et 
al., 2013; Bishop et al., 2014b; Linde et al., 2014). For example, in one study “some 
[healthcare professionals] commented that a placebo does not necessarily need to be a pill, 
but can also be a… treatment.” (Fent et al., 2011: p.3). This process definition can also 
include the belief, promoted by some researchers, that “certain physician rituals and 
behaviors… promote the placebo effect. This effect, which we refer to as the process-of-
treatment effect, has also been referred to as the context effect.” (Kermen et al., 2010: p.639). 
Other process definitions of placebos included interventions (Hróbjartsson and Norup, 2003; 
Fässler et al., 2009; Bishop et al., 2014b), healing procedures (Ferentzi et al., 2010), the 
consultation itself (Fent et al., 2011), and empathic treatment (De Gobbi et al., 2016). 
By conceiving of placebos as processes, a minority of healthcare professionals are more 
in agreement with modern scientific placebo theoretical paradigms, including the context of 
treatment (Di Blasi et al., 2001), meaning responses (Brody, 1997; Moerman, 2002), healing 
rituals and symbols (Brown, 2013; Kaptchuk and Miller, 2015; Miller and Colloca, 2010), 
and enactivism (Ongaro and Ward, 2017). By avoiding reference to material substances and 
untenable distinctions between specific and non-specific treatment, these theories focus on 
the interaction between healthcare professionals, patients, and their environment – on 
processes – and how harnessing these elements might improve symptoms. 
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Placebos as substances and processes 
Despite examples in the studies under review of process definitions that better accord 
with modern conceptions of placebos, some healthcare professionals defined placebos as both 
substances and processes (Meissner et al., 2012; Bishop et al., 2014b; De Gobbi et al., 2016; 
Fässler et al., 2009). For example, one healthcare professional defined a placebo as “a 
treatment or medication” (Bishop et al., 2014b: p. 359), and another noted that “everything I 
do or prescribe has some placebo quality” (Bishop et al., 2014b: p. 361). This highlights that 
even when healthcare professionals advocate a more viable process orientated definition, they 
may still also conceive of placebos as substances that can be prescribed to a patient. 
Rationales 
Although substance and process definitions emerged in the studies under review, as 
previously outlined healthcare professionals and patients both broadly favoured a substance 
placebo definition. However, there was less agreement over another review finding: the 
acceptable rationales for using placebos. 
Only two rationales of placebo treatment were acceptable to patients: inducing 
therapeutic benefit (Lynoe et al., 1993; Chen and Johnson, 2009; Nitzan et al., 2013; Ortiz et 
al., 2016; Bishop et al., 2014a) and giving hope (Lynoe et al., 1993; Bishop et al., 2014a). 
Although inducing therapeutic benefit was also a common rationale given by healthcare 
professionals (Comaroff, 1976; Fässler et al., 2009; Ferentzi et al., 2010; Kermen et al., 2010; 
Fent et al., 2011; Meissner et al., 2012; Howick et al., 2013), they also gave other rationales 
including managing patients (Comaroff, 1976; Hróbjartsson and Norup, 2003; Fässler et al., 
2009; Kermen et al., 2010; Fent et al., 2011; Meissner et al., 2012; Babel, 2013; Howick et 
al., 2013), coping with uncertainty (Comaroff, 1976; Kermen et al., 2010; Meissner et al., 
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2012; Linde et al., 2014), and avoiding error (Comaroff, 1976; Hróbjartsson and Norup, 
2003). This suggests that some healthcare professionals, but not patients, view placebos as 
viable clinical management tools as well as potential therapeutic treatments. 
Context 
The last major category we identified was context. In many studies, healthcare 
professionals and patients defined placebos contextually, related to the setting (Comaroff, 
1976; Kermen et al., 2010; Fent et al., 2011; Bishop et al., 2014a; Linde et al., 2014), patient 
characteristics (Hróbjartsson and Norup, 2003; Kermen et al., 2010; Fent et al., 2011; 
Ferentzi et al., 2011; De Gobbi et al., 2016; Babel, 2013; Chen and Johnson, 2009; Bishop et 
al., 2014b; Tandjung et al., 2014), and condition (Kermen et al., 2010; Fent et al., 2011; De 
Gobbi et al., 2016). The author of one study noted that “what is considered to be 'placebo 
therapy' in one situation may not be described as such in another.” (Comaroff, 1976: p.83). 
This explicitly relative notion of placebos was prevalent in a number of studies including one 
where “more than 90% of physicians expressed a strong belief that the potential benefit of 
placebos depends on the type of disease and the personality characteristics of the patient 
treated.” (Kermen et al., 2010: p.639), and another where ten of the 12 patient participants 
thought that patient characteristics influenced the placebo effect (Tandjung et al., 2014). 
A contextual understanding of placebos has implications for placebo definitions and 
rationales for placebo use. It supports process orientated definitions by identifying placebos 
as a relative concept, suggesting healthcare professionals should tailor placebo treatment to 
the specific patient, setting and condition in front of them. 
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Discussion 
Findings from our review suggest that placebo definitions used by healthcare 
professionals and patients in primary care settings can be split broadly into two categories: 
material substances, and processes. Older, untenable placebo definitions are generally 
substance orientated, whereas more modern definitions are broadly process orientated. 
However, despite advances in conceptual placebo studies research, healthcare professionals 
and patients in primary care still primarily define placebos as ‘inert’ substances. We now 
explore the implications of these findings. 
Modern placebo definitions are process orientated 
As we have previously noted, there is common consensus in the scientific literature 
that definitions characterising placebos as substances are incoherent. We posit that the move 
towards more coherent, modern definitions is characterised by an, often unsaid, metaphysical 
move from understanding placebos as material substances, to understanding them as 
processes. 
This move occurs when understanding placebos through a meaning paradigm (Brody, 
1997; Moerman, 2002), whereby placebo effects are replaced with “the psychological and 
physiological effects of meaning in the treatment of illness” (Moerman, 2002: p, 14). 
Through a ritual paradigm, whereby “in a broad sense, placebo effects are improvements in 
patients’ symptoms that are attributable to their participation in the therapeutic encounter, 
with its rituals, symbols, and interactions.” (Kaptchuk and Miller, 2015: p, 8). Or through an 
embodied (Thompson et al., 2009) or enactive paradigm, whereby placebo effects are situated 
within a system where “the parts of our bodies, our overall bodily relationship to the 
environment, and the practically and culturally meaningful structures within that 
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environment, are all co-emergent and co-dependent aspects of a single web of dynamic 
relations.” (Ongaro and Ward, 2017: p, 528). However, although meaning, ritual, or enactive 
accounts of healing processes seem useful, they struggle to effectively delineate placebo from 
non-placebo, as any kind of treatment can be conceived of in these terms. There is, however, 
one process-orientated placebo theory in which the distinction is better addressed. 
Delineating placebo from non-placebo  
Noting that the technical vocabulary used to define placebos was confusing and 
obscure, Adolf Grünbaum (1986) defined placebos as treatment processes that are remedial 
for a target disorder. He then delineated non-placebo from placebo therapy by aligning non-
placebo therapy with characteristic treatment factors, and placebo therapy with incidental 
treatment factors. The treatment factors are relative to the condition in question, and the 
therapeutic theory which states how a given therapy for a target disorder will provide clinical 
benefit. For example, the characteristic factor of a therapy involving giving amoxicillin for an 
infection would be the bacteriolytic properties of penicillin, whereas an incidental factor 
might be a patient’s expectations about the potential effect of the drug. 
Howick (2017) modified Grünbaum’s definition, presenting placebos as relative to the 
patient as well as the condition and therapeutic theory as in Grünbaum’s original version. 
This is reflected in our finding that healthcare professionals and patients conceive of placebos 
in the context of patient characteristics, as well as the setting and condition. We posit that the 
minority view of placebos as contextual treatment processes, emerging from this review, 
could be aligned with Howick’s (2017) version of Grünbaum’s definition. However, there are 
practical issues around such a definition. 
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The problems of persistent placebo substances 
Howick’s (2017) definition is credible, and aligns with some of our findings, but we 
must note that considerable theoretical manoeuvring is required to achieve this. We are left 
with placebos as contextual treatment processes, relative to a therapeutic theory, the condition 
in question, and the patient. This is in stark contrast to our finding that most healthcare 
professionals and patients conceive of placebos as inert material substances. 
In the face of critique that we should drop the placebo concept completely (e.g., 
Moerman, 2013; Nunn, 2009b; Nunn, 2009a; Turner, 2012), Howick (2017: p, 1369) noted 
that “it seems that the correct strategy for the philosopher is… to try again: to try to produce 
an acceptable account of placebos that does not fall prey to linguistic confusions.”. He may 
have achieved this, but in the face of our findings it is questionable how much clinical utility 
such a definition has in practice. As Howard Brody (1997: p, 79) noted, “it is hard to define 
‘placebo effect’ without engaging in a small-scale project to reform modern medical thinking, 
making the definition useless for the unconverted”. Our review findings suggest that such 
reform has not yet occurred. 
Implications for research 
 Our findings suggest that much research into placebos and their effects in primary 
care is undermined by incoherent definitions. There is a disconnect between modern placebo 
theories and lay definitions, but there are also differences in how researchers frame placebos 
for participants in their studies; this undermines the results of some of the studies under 
review as it is questionable what exactly they are investigating. We suggest that further 
theoretical research is required to complement empirical placebo studies. Moreover, given the 
contextual nature of the placebo phenomenon, supported by our review findings, we promote 
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more naturalistic and contextual research approaches, such as ethnography, which are 
currently underrepresented in placebo studies research. 
Implications for clinical practise 
Our review suggests there is a considerable disconnect between modern scientific 
definitions of placebos, and how healthcare professionals and patients define them. This has 
consequences. If to achieve a credible definition one has to stretch ‘placebo’ so far that only 
placebo studies researchers understand the term, it has questionable clinical utility. To 
produce ‘placebo effects’, therefore, primary healthcare professionals may be better off 
abandoning placebo terminology altogether. 
Strengths and limitations of the review 
A strength of this review is that both qualitative and quantitative studies were 
included, ensuring a broad range of findings was synthesised. However, post-hoc analysis 
showed that, although both quantitative and qualitative studies contributed to the findings, 
qualitative articles dominated. In the healthcare professionals subgroup there were four key 
articles (Comaroff, 1976; Kermen et al., 2010; Fent et al., 2011; Bishop et al., 2014b), and in 
the patients subgroup there were three (Bishop et al., 2014a; Tandjung et al., 2014; Ortiz et 
al., 2016). It has to be considered that findings from this review may be shaped by the 
findings from these seven key articles, although findings from other studies were, 
nevertheless, broadly consistent with the main line-of-argument. 
And although the abductive logic of a meta-ethnographic lines-of-argument synthesis 
allows one to create new theory from complex data by inferring the best conceived 
explanation for observed phenomena, this necessarily means that the findings are tentative; 
further inquiry is required to test the recommendations from this review. 
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Conclusion 
Based on a systematic meta-ethnographic review of 34 articles, we suggest that the 
central problem for placebos and their effects in primary care is the disconnect between 
viable modern placebo definitions and how healthcare professionals and patients define them. 
This has led to confusion and uncertainty in placebo research and clinical practice, which has 
undermined prevalence of use data and misinformed debate on clinical placebo use. 
Moreover, we suggest that once the term ‘placebo’ is stretched to its modern iteration, it may 
have limited clinical value. 
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Supplementary material 
Appendix 1: database search strategies 
MEDLINE 
1 (MH "Placebo Effect+") 
2 (MH "Placebos") 
3 1 OR 2 
4 (MH "Health Personnel+") 
5 doctor* OR clinician* OR nurse* OR GP* OR physician* OR "medical practitioner*" 
6 (MH "Patients+") 
7 patient*   
8 4 OR 5 OR 6 OR 7 
9 3 AND 8 
10 (MH "Health Facilities+") 
11 (MH "General Practice+") 
12 primary care OR primary health care OR primary healthcare OR family practice OR general 
practice OR clinical practice OR clinical setting 
13 10 OR 11 OR 12 
14 9 AND 13 
15 (MH "Randomized Controlled Trials as Topic+") 
16 "randomi?ed controlled trial*" OR RCT OR trial OR double-blind 
17 15 OR 16 
18 14 NOT 17 
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PsychINFO 
1 DE "Placebo"   
2 DE "Health Personnel" OR DE "Allied Health Personnel" OR DE "Medical Personnel" OR DE 
"Mental Health Personnel"   
3 doctor* OR clinician* OR nurse* OR GP* OR physician* OR "medical practitioner*"   
4 patient* 
5 2 OR 3 OR 4 
6 1 AND 5 
7 DE "Treatment Facilities" OR DE "Clinics" OR DE "Community Mental Health Centers" OR DE 
"Halfway Houses" OR DE "Hospitals" OR DE "Nursing Homes" OR DE "Therapeutic Camps" 
8 DE "Clinical Practice"   
9 DE "Primary Health Care"   
10 primary care OR primary health care OR primary healthcare OR family practice OR general 
practice OR clinical practice OR clinical setting 
11 7 OR 8 OR 9 OR 10 
12 6 AND 11 
13 "randomi?ed controlled trial*" OR RCT OR trial OR double-blind   
14 12 NOT 13 
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Embase Classic + Embase 
1 placebo effect/ 
2 exp health care personnel/ 
3 (doctor* or clinician* or nurse* OR GP* or physician* or "medical practitioner*").mp. 
4 patient*.mp. 
5 2 OR 3 OR 4 
6 1 AND 5 
7 exp health care facility/ 
8 general practice/   
9 (primary care or primary health care or primary healthcare or family practice or general 
practice or clinical practice or clinical setting).mp. 
10 7 OR 8 OR 9 
11 6 AND 10 
12 randomized controlled trial/ 
13 ("randomi?ed controlled trial" or RCT or trial OR double-blind).mp. 
14 12 OR 13 
15 11 NOT 14 
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CINAHL Plus with full text 
1 (MH "Placebo Effect")   
2 (MH "Placebos")   
3 1 OR 2 
4 (MH "Health Personnel+")   
5 doctor* OR clinician* OR nurse* OR GP* OR physician* OR "medical practitioner*"   
6 (MH "Patients+")   
7 patient* 
8 4 OR 5 OR 6 OR 7 
9 3 AND 8 
10 (MH "Health Facilities+")   
11 (MH "Primary Health Care")   
12 (MH "Family Practice")   
13 primary care OR primary health care OR primary healthcare OR family practice OR general 
practice OR clinical practice OR clinical setting 
14 10 OR 11 OR 12 OR 13 
15 9 AND 14 
16 (MH "Randomized Controlled Trials")   
17 "randomi?ed controlled trial*" OR RCT OR trial OR double-blind 
18 16 OR 17 
19 15 NOT 18 
 
44 
 
Web of Science 
1 TS="placebo effect*"   
2 TS=(doctor* OR clinician* OR nurse* OR GP OR physician* OR "medical practitioner*") 
3 TS=patient* 
4 2 OR 3 
5 1 AND 4 
6 TS=(primary care OR primary health care OR primary healthcare OR family practice OR 
general practice OR clinical practice OR clinical setting) 
7 5 AND 6 
8 TS=(“randomi?ed controlled trial*” OR RCT OR trial OR double-blind) 
9 7 NOT 8 
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Appendix 2: Expanded study characteristics table with summary of main findings 
 Source article Country Setting Participants (n) 
Methods of 
data 
collection 
Aims Main findings related to primary care 
1 
(Shapiro and 
Struening, 
1973a) 
USA 
General 
practice 
Hospitals 
Research 
Psychiatrists 
(119) 
Internists (50)     
GPs (14)       
Surgeons (16) 
Quantitative 
survey 
To investigate differences in the definition 
and conception of placebos among 
physicians. 
Physicians tended to align placebo use with other 
physicians and with specialties other than their own. 
Physicians tended to define placebos so their 
speciality would be excluded from the definition. 
GPs included active drugs in the definition of 
placebos more frequently than other specialties. 
2 
(Shapiro and 
Struening, 
1973b) 
USA 
General 
practice 
Hospitals 
Research 
Psychiatrists 
(117)  
Internists (50)        
GPs (14)       
Surgeons (14) 
Quantitative 
survey 
To assess ethical attitudes towards the use 
of placebos in treatment and research. 
Older physicians and those who spent more time in 
private practice were more critical of placebo use. 
Physicians who were more research active were less 
critical of placebo use. 
GPs were generally critical towards placebo use. 
3 
(Shapiro and 
Struening, 
1974) 
USA 
General 
practice 
Hospitals 
Research 
Psychiatrists 
(114)  
Internists (48)        
GPs (15)       
Surgeons (14) 
Quantitative 
survey 
To assess the tendency of physicians to 
attribute the use of placebos or nonspecific 
treatment to other physicians. 
Physicians generally attributed the use of placebos or 
nonspecific treatment to other physicians and 
specialties more than themselves. However, GPs 
were less likely to do this. 
Physicians tended to exclude their own specialty from 
their definition of placebos. 
4 (Comaroff, 1976) UK 
General 
practice GPs (51) 
Qualitative 
observation 
Interviews 
To investigate how doctors, as placebo 
prescribers, perceive and employ the 
placebo concept. 
Placebo use was primarily identified as a process by 
which physicians managed patients, maintained their 
social role or coped with medical uncertainty. 
5 
(Thomson and 
Buchanan, 
1982) 
New 
Zealand 
General 
practice GPs (44) 
Quantitative 
survey 
To determine GPs’ basic understanding of 
the placebo effect and their views on the use 
of placebo treatments. 
Most GPs would deliberately use a placebo treatment 
in some circumstances. However, GPs tended to 
downplay their use of placebos compared with that of 
colleagues. 
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 Source article Country Setting Participants (n) 
Methods of 
data 
collection 
Aims Main findings related to primary care 
6 (Lynoe et al., 1993) Sweden 
Primary 
healthcare 
centre 
University 
Physicians 
associated with 
a university 
(47) 
GPs (47)   
Patients (83) 
Mainly 
quantitative 
survey with 
some open 
ended 
questions 
To investigate the attitudes of patients and 
physicians toward placebo treatment. 
Regarding placebo treatment, patients were generally 
more paternalistic than physicians. 
For GPs, the use of ‘impure placebos’ was more 
acceptable than ‘pure placebos’. 
7 
(Hróbjartsson 
and Norup, 
2003) 
Denmark 
General 
practice 
Private 
practice 
Hospitals 
GPs (182) 
Hospital 
physicians 
(185) 
Private 
specialists 
(136) 
Quantitative 
survey 
To investigate the proportion and types of 
placebo intervention, conditions of use, and 
attitudes towards use. 
86% of GPs used placebo interventions at least once, 
and 48% used placebo interventions more than ten 
times in the last year. 
46% of GPs found placebos ethically acceptable. 
30% of GPs believe placebos affect ‘objective 
outcomes’. 
The main reason for using placebos was to avoid a 
confrontation with a patient. 
8 
(Nitzan and 
Lichtenberg, 
2004) 
Israel 
Hospitals 
Community 
clinics 
Hospital 
physicians (31) 
Head nurses 
(31) 
Family 
physicians (27) 
Quantitative 
survey 
To gauge the frequency and circumstances 
of, and attitude towards, placebo use in 
clinical practice. 
60% of participants used placebos. 
94% found placebos ‘generally or occasionally 
effective’. 
Family physicians’ most common reason for use was 
to manage patients. 
9 
(Chen and 
Johnson, 
2009) 
New 
Zealand 
Primary 
Care Clinics Patients (211) 
Quantitative 
survey 
To examine patients beliefs about the 
placebo effect, views on the use of placebos 
in clinical practice, and their willingness to 
participate in a placebo-controlled RCT. 
Patients thought placebo use appropriate when it is 
for therapeutic benefit, requested by the patient, or 
when no other treatments are available. 
Patients thought placebo use inappropriate when it is 
for the benefit of the physician or when it ‘seemed 
dangerous’. 
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 Source article Country Setting Participants (n) 
Methods of 
data 
collection 
Aims Main findings related to primary care 
10 (Fässler et al., 2009) Switzerland 
General 
practice 
Private 
practice 
Paediatricians 
(67) 
Urban GPs (41) 
Suburban GPs 
(55) 
Rural GPs (70) 
Quantitative 
survey 
To investigate to what extent and in which 
way Swiss primary care providers use 
placebo interventions. 
More participants used impure placebos (57%) than 
pure placebos (17%). Paediatricians used pure 
placebos and deception more than GPs. 
The most common premise for placebo use was that 
they can be used in partnership with patients. 
Impure placebos were deemed more ethically 
acceptable than pure placebos, although participants 
were uncertain about the ethical legitimacy of placebo 
use. 
11 (Ferentzi et al., 2010) Hungary 
General 
practice GPs (94) 
Quantitative 
survey 
To investigate how GPs in Hungary 
perceived some important aspects of their 
own placebo use. 
(Preliminary report) 
Over 80% of GPs used placebos, most commonly for 
symptoms such as ‘anxiety, fatigue, sleep disorders 
and functional problems’. 
Most GPs (84%) considered placebo use ethical 
when conducted for therapeutic benefit. 
Physicians called for official guidance on placebo 
use. 
12 (Kermen et al., 2010) USA 
Family 
practice 
Family 
physicians 
(412) 
Mainly 
quantitative 
survey with 
some open 
ended 
questions 
To gain a better understanding of the role of 
placebos in clinical practice on a national 
level. 
56% had used a placebo in clinical practice. 
40% had used an antibiotic as a placebo and 11% 
had used ‘inert substances’. 
85% believed placebos have both ‘psychological and 
physical benefits’. 
61% recommended a placebo rather than no 
treatment. 
97% believed that doctors’ rituals and/or behaviours 
contribute to placebo effects. 
The most common reason for placebo use was ‘after 
unjustified demand for medication’. 
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 Source article Country Setting Participants (n) 
Methods of 
data 
collection 
Aims Main findings related to primary care 
13 (Fässler et al., 2011) Switzerland 
Primary 
care  
GPs (232) 
Patients (414) 
Quantitative 
survey with 
one open-
ended 
question 
To compare the proportions of patients and 
physicians who would accept therapies that 
work by enhancing self-healing capacities 
and by exploiting contextual factors. 
87% of patients and 97% of GPs thought that belief in 
a therapy can improve ‘physical complaints’. 
Patients supported placebo treatment more than 
GPs. 
90% of GPs admitted to using treatments that take 
advantage of ‘non-specific effects’. 
70% of patients wanted to be informed about non-
specific treatments, yet GPs thought this figure would 
only be 33%. 
14 (Fent et al., 2011) Switzerland 
Primary 
care 
GPs (8) 
Internists (2) 
Paediatrician 
(1) 
Psychiatrist (1) 
Semi-
structured 
interviews 
To explore physicians’ views on the use of 
placebos in daily practice. 
Most participants described placebos as ‘pure 
placebos’; most ‘impure placebos’ were not regarded 
as placebos. 
Participants used placebos mostly when there was 
‘no satisfactory somatic explanation’. 
Participants generally were unclear on the ethical 
status of placebo treatment, were uncertain how to 
communicate such treatment to patients, and would 
welcome more guidance. 
15 (Ferentzi et al., 2011) Hungary 
General 
practice GPs (169) 
Quantitative 
survey 
To provide a detailed description of 
physicians’ attitudes toward, and knowledge 
of, clinical placebo use. 
(Full report of no.11) 
83% of participants had used placebos. 
Most participants regarded placebos as both ethical 
and effective. 
16 (Kisaalita et al., 2011) USA University 
Members of the 
public (103) 
Quantitative 
survey with 
experimental 
component 
To examine the acceptability and ethics of 
placebo treatment for pain. 
Placebos described as ‘medication shown to be a 
powerful analgesic in some people’ were perceived to 
be as deceptive as those described as ‘standard drug 
treatment’. 
Participants ‘tolerated moderate effectiveness and 
considerable negative consequences in an 
acceptable placebo’. 
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 Source article Country Setting Participants (n) 
Methods of 
data 
collection 
Aims Main findings related to primary care 
17 (Babel, 2012) Poland Primary care 
Primary care 
physicians 
(190) 
Quantitative 
survey with 
experimental 
component 
To identify factors that contribute to the high 
variability of the rates of use of placebo 
interventions reported in questionnaire 
surveys. 
Participants asked about ‘placebo interventions’ said 
the never used them significantly more than 
participants asked about ‘nonspecific treatment 
methods’. 
18 
(Kisaalita and 
Robinson, 
2012) 
USA University Members of the public (100) 
Quantitative 
survey with 
open-ended 
question 
To examine the acceptability, efficacy and 
knowledge of analgesic placebo treatments. 
Participants mostly thought of placebos as inert and 
had differing views regarding the effectiveness of 
placebo treatment. 
19 
(Koteles and 
Ferentzi, 
2012) 
Hungary Online news site 
Members of the 
public (6104) 
Quantitative 
survey 
To assess the attitudes of laypeople toward 
deceptive clinical placebo use. 
Participants thought ‘helping patients is more 
important than avoiding deception’ illustrating a 
pragmatic view towards placebo treatment. 
20 (Meissner et al., 2012) Germany 
General 
practice GPs (208) 
Quantitative 
survey 
To collect data on the use of placebo 
interventions by GPs in Germany. 
88% of GPs had used a placebo at least once. 
The use of ‘impure placebo’s was more common than 
‘pure placebos’. 
The main reason for placebo treatment was ‘a 
possible psychological effect’, although patient 
expectation was also a common reason. 
Most GPs thought placebo treatment ethical if used to 
elicit a psychological effect. 
21 (Babel, 2013) Poland Primary care 
Primary care 
physicians 
(169) 
Quantitative 
survey 
To investigate the behaviour beliefs and 
attitudes of Polish primary care physicians 
concerning the use of placebo interventions. 
80% of participants used placebo interventions. The 
most common placebos were vitamins and 
homeopathy. 
84% thought placebos effective, but 54% thought 
them only effective for patients with ‘subjective 
symptoms’. 
73% thought individual traits were important for 
effectiveness. 65% thought patients’ expectations 
important. 
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 Source article Country Setting Participants (n) 
Methods of 
data 
collection 
Aims Main findings related to primary care 
22 (Howick et al., 2013) UK 
Primary 
care GPs (783) 
Quantitative 
survey 
To investigate the prevalence of placebo use 
in UK primary care. 
12% of GPs had used pure placebos and 97% had 
used impure placebos, at least once. 
1% used pure placebos and 77% used impure 
placebos at least once a week. 
Most (66% for pure, 84% for impure) GPs thought 
placebos ethical in ‘some circumstances’. 
23 (Hull et al., 2013) USA 
Primary 
Care 
Patients with 
chronic illness 
(853) 
Quantitative 
survey 
To examine the attitudes of US patients 
about the use of placebo treatments in 
medical care. 
50-84% of participants thought placebo treatment 
acceptable depending on ‘doctors’ level of certainty 
about the benefits and safety of the treatment, the 
purpose of the treatment, and the transparency with 
which the treatment was described to patients’. 
22% of participants thought placebo treatment 
unacceptable. 
24 (Linde et al., 2013) Germany 
General 
practice 
GPs (84) 
Internists (3) 
Orthopaedists 
(1) 
Quantitative 
survey 
(n=80) 
Cognitive 
interviews 
(N=7) 
To develop a questionnaire. 
The questions on ‘typical placebos and 
complementary treatments’ were understandable and 
‘easy to answer’. However, interviews suggest that 
these issues are ‘difficult to grasp in a quantitative 
survey’. 
The concept ‘non-specific treatment’ was thought 
vague. 
Study authors suggest direct observation would be a 
useful data collection method. 
25 (Nitzan et al., 2013) Israel 
Academic 
centres Students (344) 
Quantitative 
survey 
To investigate the opinions of healthy 
students regarding the acceptability of 
placebo treatment if they were to experience 
depression. 
70% of participants would agree to placebo treatment 
as ‘a first-line treatment’. 
88% of participants did not think placebo treatment 
deceitful. 
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 Source article Country Setting Participants (n) 
Methods of 
data 
collection 
Aims Main findings related to primary care 
26 (Bishop et al., 2014a) UK Community 
General public 
(58) 
Focus 
groups 
To identify when and why placebo-
prescribing in primary care might be 
acceptable and unacceptable to patients 
Participants had two broad perspectives: 
‘consequentialist’, whereby they focussed on the 
potential benefits of placebo treatment; and 
‘respecting autonomy’, whereby they focussed on the 
negative effects of deception in treatment. 
‘Placebo’ was generally thought to mean ‘ineffective’. 
Some participants thought the careful use of 
language may enable ethical placebo treatment. 
27 (Bishop et al., 2014b) UK 
General 
practice GPs (783) 
Qualitative 
survey 
To explore GPs’ perspectives on clinical 
uses of placebos. 
GPs generally defined placebos negatively, as in 
‘lacking something’. 
GPs described myriad possible’ harms and benefits 
of placebo prescribing’. 
Some GPs thought placebos beneficial, although 
some thought they should not be used for ethical 
reasons. 
28 (Linde et al., 2014) Germany 
Private 
practice 
GPs (319) 
Internists (311) 
Orthopaedists 
(305) 
Quantitative 
survey 
To investigate the use of placebos and non-
specific treatments among physicians 
working in private practices in Germany, and 
how such use is associated with the belief in 
and the use of complementary and 
alternative treatments. 
30% of GPs had used non-specific therapies; 35%, 
had used placebos or ‘non-specific therapies’. 
Use of pure and/or impure placebos was associated 
with ‘being a GP, being an internist, and having 
unorthodox professional views’. 
29 (Tandjung et al., 2014) Switzerland Community Patients (12) 
Semi-
structured 
interviews 
To explore patients’ conceptualisation, 
experiences and attitudes regarding the use 
of placebos in daily clinical practice. 
Participants mostly defined placebos as something 
matching the definition of ‘pure placebos’. 
Most participants believed placebos’ mainly worked 
via psychological effects’. 
The acceptability of placebo use was generally 
related to treatment success. 
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 Source article Country Setting Participants (n) 
Methods of 
data 
collection 
Aims Main findings related to primary care 
30 (Linde et al., 2015) Germany 
Private 
practice 
Family 
physicians 
(319) 
Internists (311) 
Orthopaedists 
(305) 
Quantitative 
survey 
To investigate to what extent family 
physicians, internists and orthopaedists 
working in private practice in Germany 
believe in the efficacy of, and use, CAM 
therapies.  
Family physicians’ agreed more with statements on 
the need of more time and the patient–doctor 
relationship’. 
Family physicians were more positive about utilising 
placebos than internists or orthopaedists. 
31 (De Gobbi et al., 2016) Italy 
General 
practice GPs (62) 
Quantitative 
survey 
To investigate placebo use by general 
practitioners throughout their everyday 
practice: in particular the frequency of use, 
placebo features, instructions, and conditions 
of use. 
84% of GPs had used a placebo in the last 6 months. 
Placebo were mainly used for ‘problems of low 
clinical significance’ (85%).  
13% of GPs had given ‘pure placebos’. 
Reasons for giving placebos included for ‘frequent 
attenders’ and for patients with ‘unexplained 
symptoms’. 
None of the GPs used placebo treatment openly. 
32 (Feffer et al., 2016) Israel 
Outpatient 
clinic 
Patients with 
depression (96) 
Healthy 
members of the 
public (114) 
Quantitative 
survey 
To assess the acceptability of placebo usage 
among depressed patients 
57% of patients with depression and 71% of healthy 
members of the public would give consent for 
placebo treatment for future depression 
72% of patients with depression and 78% of healthy 
members of the public would give consent for 
placebo treatment for general medical conditions. 
33 (Ortiz et al., 2016) USA 
Primary 
care Patients (853) 
Qualitative 
survey 
To examine qualitative responses regarding 
the use of placebo treatments in medical 
care in a sample of US patients. 
‘Lack of harm’ and ‘potential benefit’ were the most 
common acceptable justifications for placebo use.  
Participants who did not think placebo use acceptable 
most commonly thought that doctors are obliged to 
‘do more’. 
The following other themes emerged: ‘the issue of 
whether a doctor was transparent about placebo use, 
including honesty’; patients’ ‘right to know’; and the 
‘power of the mind’. 
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 Source article Country Setting Participants (n) 
Methods of 
data 
collection 
Aims Main findings related to primary care 
34 (Faria et al., 2017) USA Community Parents (1000) 
Quantitative 
survey 
To assess parental attitudes regarding 
placebo use in paediatric randomized 
controlled trials and clinical care. 
86% of parents considered placebo use acceptable in 
some paediatric care situations. 
6% of parents found the use of placebos in children 
‘always unacceptable’. 
The acceptability of placebo treatment was influenced 
by factors including: doctors’ opinions on the 
therapeutic benefit of the treatment; the conditions of 
use; transparency; safety; and the ‘purity of 
placebos’. 
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Appendix 3: Quality assessment 
MMAT Methodological Criteria Assessment 
http://mixedmethodsappraisaltoolpublic.pbworks.com/w/file/fetch/84371689/MMAT%202011%20criteria%20and%20tutorial%202011-06-29updated2014.08.21.pdf  
 
 
Initial screening questions for inclusion in MMAT assessment 
Are there clear qualitative and quantitative research questions (or objectives*), or a clear mixed methods question (or objective*)? Yes No Can’t tell 
Do the collected data address the research question (objective)? E.g., consider whether the follow-up period is long enough for the 
outcome to occur (for longitudinal studies or study components). Yes No Can’t tell 
 
Overall score 
No of studies Percent Rating 
33 97 Yes 
0 0 No 
1 3 Can’t tell 
 
Total number of included studies 
Number 33 
Percent 97 
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MMAT criteria 
Types of mixed methods study 
components or primary studies 
Methodological quality criteria (Yes/No/Can’t tell) 
1. Qualitative 
1.1. Are the sources of qualitative data (archives, documents, informants, observations) relevant to address the research question (objective)? 
1.2. Is the process for analyzing qualitative data relevant to address the research question (objective)? 
1.3. Is appropriate consideration given to how findings relate to the context, e.g., the setting, in which the data were collected? 
1.4. Is appropriate consideration given to how findings relate to researchers’ influence, e.g., through their interactions with participants? 
2. Quantitative randomized controlled 
(trials) 
2.1. Is there a clear description of the randomization (or an appropriate sequence generation)? 
2.2. Is there a clear description of the allocation concealment (or blinding when applicable)? 
2.3. Are there complete outcome data (80% or above)? 
2.4. Is there low withdrawal/drop-out (below 20%)? 
3. Quantitative nonrandomized   
3.1. Are participants (organizations) recruited in a way that minimizes selection bias? 
3.2. Are measurements appropriate (clear origin, or validity known, or standard instrument; and absence of contamination between groups when 
appropriate) regarding the exposure/intervention and outcomes? 
3.3. In the groups being compared (exposed vs. non-exposed; with intervention vs. without; cases vs. controls), are the participants comparable, or do 
researchers take into account (control for) the difference between these groups? 
3.4. Are there complete outcome data (80% or above), and, when applicable, an acceptable response rate (60% or above), or an acceptable follow-up 
rate for cohort studies (depending on the duration of follow-up)? 
4. Quantitative descriptive 
4.1. Is the sampling strategy relevant to address the quantitative research question (quantitative aspect of the mixed methods question)? 
4.2. Is the sample representative of the population understudy? 
4.3. Are measurements appropriate (clear origin, or validity known, or standard instrument)? 
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4.4. Is there an acceptable response rate (60% or above)? 
5. Mixed methods 
5.1. Is the mixed methods research design relevant to address the qualitative and quantitative research questions (or objectives), or the qualitative 
and quantitative aspects of the mixed methods question (or objective)? 
5.2. Is the integration of qualitative and quantitative data (or results*) relevant to address the research question (objective)? 
5.3.   Is appropriate consideration given to the limitations associated with this integration, e.g., the divergence of qualitative and quantitative data (or 
results*) in a triangulation design? 
Criteria for the qualitative component (1.1 to 1.4), and appropriate criteria for the quantitative component (2.1 to 2.4, or 3.1 to 3.4, or 4.1 to 4.4), must 
be also applied 
 
Key 
Criteria met (%) Rating 
100 **** 
75 *** 
50 ** 
25 * 
0  
 
NB: ‘Can’t tell’ (C) is scored as ‘No’ (N). 
 
Overall Score 
No of studies Percent Rating 
6 18 **** 
15 46 *** 
12 36 ** 
0 0 * 
0 0  
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Assessment 
No Study title Lead author Year Comments Criteria score (Y/N/C) Overall score 
1 Defensiveness in the definition of placebo Shapiro 1973 Risk of selection bias. 
3.1 3.2 3.3 3.4 
*** 
N Y Y Y 
2 The use of placebos: A study of ethics and physicians' attitudes Shapiro 1973 Risk of selection bias. 
3.1 3.2 3.3 3.4 
*** 
N Y Y Y 
3 
A comparison of the attitudes of a sample of 
physicians about the effectiveness of their 
treatment and the treatment of other 
physicians 
Shapiro 1974 Risk of selection bias. 
3.1 3.2 3.3 3.4 
*** 
N Y Y Y 
4 A bitter pill to swallow: placebo therapy in general practice Comaroff 1976 
Study is appropriate for the research question. The 
researcher reflects on how the findings relate to 
the context and her disciplinary assumptions. The 
analytic process is not clear. 
    
Did not meet 
screening criteria 
    
5 Placebos and general practice: attitudes to, and the use of, the placebo effect Thomson 1982 
Participant recruitment methods do not minimise 
bias. Small sample size.  
4.1 4.2 4.3 4.4 
** 
N Y N Y 
6 
The attitudes of patients and physicians 
toward placebo treatment - A comparative 
study 
Lynoe 1993 
The patient group is more heterogeneous than the 
groups of physicians. Patients sampled 
consecutively. 
3.1 3.2 3.3 3.4 
*** 
N Y Y Y 
7 
The use of placebo interventions in medical 
practice - A national questionnaire survey of 
Danish clinicians 
Hrobjartsson 2003 Study is appropriate, well designed and well conducted. 
3.1 3.2 3.3 3.4 
**** 
Y Y Y Y 
8 Questionnaire survey on use of placebo Nitzan 2004 Sample not representative. 3.1 3.2 3.3 3.4 ** 
58 
 
No Study title Lead author Year Comments Criteria score (Y/N/C) Overall score 
N Y N Y 
9 Patients' attitudes to the use of placebos: results from a New Zealand survey Chen 2009 Low response rate.  
4.1 4.2 4.3 4.4 
*** 
Y Y Y N 
10 Use of placebo interventions among Swiss primary care providers Fassler 2009 
Low response rate. Demographic information is 
only available for the whole sample, not each 
group. 
3.1 3.2 3.3 3.4 
** 
Y Y C N 
11 
The Therapeutic use of placebos among 
Hungarian GPs: A preliminary research 
report 
Ferentzi 2010 Very low response rate. Not enough information to determine if the sample is representative 
4.1 4.2 4.3 4.4 
** 
Y C Y N 
12 
Family physicians believe the placebo effect 
is therapeutic but often use real drugs as 
placebos 
Kermen 2010 Low response rate. 
4.1 4.2 4.3 4.4 
*** 
Y Y Y N 
13 
Placebo interventions in practice: A 
questionnaire survey on the attitudes of 
patients and physicians 
Fassler 2011 Well conducted study. High response rate. 
3.1 3.2 3.3 3.4 
**** 
Y Y Y Y 
14 
The use of pure and impure placebo 
interventions in primary care - a qualitative 
approach 
Fent 2011 
Researchers do not reflect in any detail on how 
their influence may have affected results. Little 
contextual exploration. 
1.1 1.2 1.3 1.4 
** 
Y Y N N 
15 
The use of placebos in medical practice. A 
questionnaire survey among GPs of 
Hungary 
Ferentzi 2011 Very low response rate. 
4.1 4.2 4.3 4.4 
** 
Y C Y N 
16 Factors affecting placebo acceptability: deception, outcome, and disease severity Kisaalita 2011 
Sample likely not representative of the population. 
No response rate recorded. 
3.1 3.2 3.3 3.4 
** 
N Y Y C 
17 Babel 2012 No record of response rate.  3.1 3.2 3.3 3.4 *** 
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No Study title Lead author Year Comments Criteria score (Y/N/C) Overall score 
The Effect of Question Wording in 
Questionnaire Surveys on Placebo Use in 
Clinical Practice 
Y Y Y C 
18 Analgesic Placebo Treatment Perceptions: Acceptability, Efficacy, and Knowledge Kisaalita 2012 
Sample likely not representative of the population. 
No response rate recorded. 
3.1 3.2 3.3 3.4 
** 
N Y Y C 
19 Ethical aspects of clinical placebo use: what do laypeople think? Koteles 2012 Sample not representative. 
3.1 3.2 3.3 3.4 
*** 
N Y Y Y 
20 Widespread use of pure and impure placebo interventions by GPs in Germany Meissner 2012 Low response rate 
4.1 4.2 4.3 4.4 
*** 
Y Y Y N 
21 Use of Placebo Interventions in Primary Care in Poland Babel 2013 
Results might not be representative of the 
population. 
4.1 4.2 4.3 4.4 
*** 
Y N Y Y 
22 
Placebo use in the United kingdom: results 
from a national survey of primary care 
practitioners 
Howick 2013 Low response rate. 
4.1 4.2 4.3 4.4 
*** 
Y Y Y N 
23 Patients' attitudes about the use of placebo treatments: telephone survey Hull 2013 
Low response rate. Demographic data only 
available for whole sample. Inferential statistical 
results not recorded. 
4.1 4.2 4.3 4.4 
** 
Y Y N N 
24 
Use of Placebos and Nonspecific and 
Complementary Treatments by German 
Physicians - Rationale and Development of 
a Questionnaire for a Nationwide Survey 
Linde 2013 Method of analysis is quite vague. Very little primary data reported. 
1.1 1.2 1.3 1.4 
** 
Y N Y N 
25 Nitzan 2013 Sample not representative. 4.1 4.2 4.3 4.4 *** 
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No Study title Lead author Year Comments Criteria score (Y/N/C) Overall score 
Consenting not to be informed: a survey on 
the acceptability of placebo use in the 
treatment of depression 
N Y Y Y 
26 
When and why placebo-prescribing is 
acceptable and unacceptable: a focus group 
study of patients' views 
Bishop 2014 Well designed and conducted. 
1.1 1.2 1.3 1.4 
**** 
Y Y Y Y 
27 
Placebo use in the UK: a qualitative study 
exploring GPs' views on placebo effects in 
clinical practice 
Bishop 2014 Well designed and conducted. 
1.1 1.2 1.3 1.4 
**** 
Y Y Y Y 
28 
The use of placebo and non-specific 
therapies and their relation to basic 
professional attitudes and the use of 
complementary therapies among German 
physicians--a cross-sectional survey 
Linde 2014 Low response rate. 
3.1 3.2 3.3 3.4 
*** 
Y Y Y N 
29 The patient’s perspective of placebo use in daily practice: a qualitative study Tandjung 2014 Appropriate consideration to reflexivity not given. 
1.1 1.2 1.3 1.4 
*** 
Y Y Y N 
30 
Belief in and use of complementary 
therapies among family physicians, 
internists and orthopaedists in Germany -
cross-sectional survey 
Linde 2015 Low response rate. 
3.1 3.2 3.3 3.4 
*** 
Y Y Y N 
31 Placebo in general practice De Gobbi 2016 Sample not representative. 
4.1 4.2 4.3 4.4 
** 
Y N C Y 
32 A comparative study with depressed patients on the acceptability of placebo use Feffer 2016 Well designed and conducted. 
3.1 3.2 3.3 3.4 
**** 
Y Y Y Y 
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No Study title Lead author Year Comments Criteria score (Y/N/C) Overall score 
33 
Patient attitudes about the clinical use of 
placebo: qualitative perspectives from a 
telephone survey 
Ortiz 2016 
 
 
Low response rate. No contextual or reflexive 
consideration for qualitative component. 
 
5.1 5.2 5.3 
** 
Y Y N 
1.1 1.2 1.3 1.4 
Y Y N N 
4.1 4.2 4.3 4.4 
Y C Y N 
34 Parental Attitudes About Placebo Use in Children Faria 2017 Well designed and conducted. 
4.1 4.2 4.3 4.4 
**** 
Y Y Y Y 
 
 
